5090792026-01-012026-03-315090792026-03-315090792025-03-315090792025-04-012026-03-315090792026-01-012026-03-31in-capmkt:OtherExpenses1Member5090792025-04-012026-03-31in-capmkt:OtherExpenses1Member5090792026-03-31OtherNoncurrentFinancialAssetsDomain15090792026-03-31OtherNoncurrentFinancialAssetsDomain25090792026-03-31OtherCurrentAssetsDomain15090792026-03-31OtherNoncurrentFinancialLiabilitiesDomain15090792026-03-31OtherCurrentFinancialLiabilitiesDomain15090792026-03-31OtherCurrentLiabilitiesDomain15090792026-01-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15090792025-04-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15090792026-01-012026-03-31RelatedPartyTransactionDomain15090792025-12-31RelatedPartyTransactionDomain15090792026-03-31RelatedPartyTransactionDomain15090792026-01-012026-03-31RelatedPartyTransactionDomain25090792025-12-31RelatedPartyTransactionDomain25090792026-03-31RelatedPartyTransactionDomain25090792026-01-012026-03-31RelatedPartyTransactionDomain35090792025-12-31RelatedPartyTransactionDomain35090792026-03-31RelatedPartyTransactionDomain35090792026-01-012026-03-31RelatedPartyTransactionDomain45090792025-12-31RelatedPartyTransactionDomain45090792026-03-31RelatedPartyTransactionDomain45090792026-01-012026-03-31RelatedPartyTransactionDomain55090792025-12-31RelatedPartyTransactionDomain55090792026-03-31RelatedPartyTransactionDomain55090792026-01-012026-03-31RelatedPartyTransactionDomain65090792025-12-31RelatedPartyTransactionDomain65090792026-03-31RelatedPartyTransactionDomain65090792026-01-012026-03-31RelatedPartyTransactionDomain75090792025-12-31RelatedPartyTransactionDomain75090792026-03-31RelatedPartyTransactionDomain75090792026-01-012026-03-31RelatedPartyTransactionDomain85090792025-12-31RelatedPartyTransactionDomain85090792026-03-31RelatedPartyTransactionDomain85090792026-01-012026-03-31RelatedPartyTransactionDomain95090792025-12-31RelatedPartyTransactionDomain95090792026-03-31RelatedPartyTransactionDomain95090792026-01-012026-03-31RelatedPartyTransactionDomain105090792025-12-31RelatedPartyTransactionDomain105090792026-03-31RelatedPartyTransactionDomain105090792026-01-012026-03-31RelatedPartyTransactionDomain115090792025-12-31RelatedPartyTransactionDomain115090792026-03-31RelatedPartyTransactionDomain115090792026-01-012026-03-31RelatedPartyTransactionDomain125090792025-12-31RelatedPartyTransactionDomain125090792026-03-31RelatedPartyTransactionDomain125090792026-01-012026-03-31RelatedPartyTransactionDomain135090792025-12-31RelatedPartyTransactionDomain135090792026-03-31RelatedPartyTransactionDomain135090792026-01-012026-03-31RelatedPartyTransactionDomain145090792025-12-31RelatedPartyTransactionDomain145090792026-03-31RelatedPartyTransactionDomain145090792026-01-012026-03-31RelatedPartyTransactionDomain155090792025-12-31RelatedPartyTransactionDomain155090792026-03-31RelatedPartyTransactionDomain155090792026-01-012026-03-31RelatedPartyTransactionDomain165090792025-12-31RelatedPartyTransactionDomain165090792026-03-31RelatedPartyTransactionDomain165090792026-01-012026-03-31RelatedPartyTransactionDomain175090792025-12-31RelatedPartyTransactionDomain175090792026-03-31RelatedPartyTransactionDomain175090792026-01-012026-03-31RelatedPartyTransactionDomain185090792025-12-31RelatedPartyTransactionDomain185090792026-03-31RelatedPartyTransactionDomain185090792026-01-012026-03-31RelatedPartyTransactionDomain195090792025-12-31RelatedPartyTransactionDomain195090792026-03-31RelatedPartyTransactionDomain195090792026-01-012026-03-31RelatedPartyTransactionDomain205090792025-12-31RelatedPartyTransactionDomain205090792026-03-31RelatedPartyTransactionDomain205090792026-01-012026-03-31RelatedPartyTransactionDomain215090792025-12-31RelatedPartyTransactionDomain215090792026-03-31RelatedPartyTransactionDomain215090792026-01-012026-03-31RelatedPartyTransactionDomain225090792025-12-31RelatedPartyTransactionDomain225090792026-03-31RelatedPartyTransactionDomain225090792026-01-012026-03-31RelatedPartyTransactionDomain235090792025-12-31RelatedPartyTransactionDomain235090792026-03-31RelatedPartyTransactionDomain235090792026-01-012026-03-31RelatedPartyTransactionDomain245090792025-12-31RelatedPartyTransactionDomain245090792026-03-31RelatedPartyTransactionDomain245090792026-01-012026-03-31RelatedPartyTransactionDomain255090792025-12-31RelatedPartyTransactionDomain255090792026-03-31RelatedPartyTransactionDomain255090792026-01-012026-03-31RelatedPartyTransactionDomain265090792025-12-31RelatedPartyTransactionDomain265090792026-03-31RelatedPartyTransactionDomain265090792026-01-012026-03-31AuditorDomain1iso4217:INRxbrli:pureiso4217:INRxbrli:shares509079GUFICBIONOTLISTEDINE742B01025GUFIC BIOSCIENCES LIMITEDMain BoardEquity2025-04-012026-03-312026-05-292026-05-22INRLakhsQuarterlyFourth quarterSingle segmentThe Company's business activity falls within a single operating segment i.e. Pharmaceuticals2026-05-2919:30:002026-05-2921:05:00trueCash Flow IndirectDeclaration of unmodified opiniontruetrueNANAfalsetrue2024-12-27https://gufic.com/wp-content/uploads/2024/12/Related%20party%20transactions%20policy.pdffalsefalseThe Company has not defaulted in payment of interest/ instalment obligations on loans from Banks and Financial Institutions. Further, the Company does not have any outstanding debt securities (including Commercial Paper), Medium Term Notes (MTNs), Foreign Currency Convertible Bonds (FCCBs), External Commercial Borrowings (ECBs), etc. 2026-01-012026-03-31AuditedStandalone2520523000-119580002508565000124269700089544000-18055100038144700094373000764850005282810002232276000276289000027628900046325000242200007054500002057440000000205744000499300021073700010028300012.052.05002.052.050001. The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards), Rules, 2015 (Ind AS) as amended, prescribed under section 133 of Companies Act, 2013, read with rules issued thereunder. <BR> <BR> 2. The above results for the quarter and year ended March 31, 2026 have been reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on May 29, 2026. The Statutory Auditors have carried out audit of the results for quarter and year ended March 31, 2026. <BR> <BR> 3. The Company's business activity falls within a single operating segment i.e. Pharmaceuticals. <BR> <BR> 4. The Board of Directors at its meeting held on May 29, 2026 has recommended a final dividend of Re. 0.10/- per equity share i.e. @ 10% on the face value of Re. 1/- each, for the financial year 2025-26, subject to the approval of the shareholders at the ensuing Annual General Meeting. <BR> <BR> 5. The equity shares and basic/diluted earnings per share has been presented in accordance with Ind AS - 33-Earning per share. <BR> <BR> 6. The figures for the quarter ended March 31, 2026 and March 31, 2025 are balancing figures between audited figures in respect of the full financial year and the unaudited published year-to -date figures up to the third quarter ended December 31, 2025 and December 31, 2024 respectively, which were subjected to limited review. <BR> <BR> 7. Previous year/quarters figures have been regrouped/reclassified, wherever necessary.2025-04-012026-03-31AuditedStandalone94047540002582100094305750004253250000647308000-688557000151680800036611400030832400021724780008575725000854850000085485000013702500086338000223363000063148700000006314870004993000636480000100283000165415420006.36.3006.36.3000Other Expenses528281000Other Expenses217247800048485260002214460000061619000000287090000522200024775900028169000005413281000324466600002973967000603249000140311000661400037241410001571100010180850008002603000001341588400010028300065415420006641825000664182500010503550000001992660001249621000180027000165735000015953830002801269000481300019859400001990753000212408000500443000011045400045182000186100005178676000677405900013415884000Other financial assests114135000Other non-current assets133624000Other current assets1018085000Other non-current financial liabilities199266000Other current financial liabilities212408000Other current liabilities110454000354531000-1075976000-2363250000005564000003641590000003083240000000004000152390000000-127200000-2962380005586120000001184150000440197000061400000000015000311812000000000000000000004000100870000-7322000-30964200000174500000000100251900025464100085800000100280003280640000-21250003236060004541610000454161000149088000603249000Items that will not be reclassified to Profit or Loss66720006672000Items that will not be reclassified to Profit or Loss66720006672000167900016790000049930004993000Gufic Biosciences Limited******Gufic Private Limited******Enterprise over which Key Managerial Personnel are able to exercise significant influenceAny other transactionReceiving of Services4500000Approved1820000-664000-352000Gufic Biosciences Limited******Gufic Private Limited******Enterprise over which Key Managerial Personnel are able to exercise significant influenceAny other transactionLease Rental paid42000000Approved2100000000Gufic Biosciences Limited******Gufic Private Limited******Enterprise over which Key Managerial Personnel are able to exercise significant influenceAny other transactionInterest Free Security Deposit given against Lease-03500000035000000Gufic Biosciences Limited******Gufic Chem Private Limited******Enterprise over which Key Managerial Personnel are able to exercise significant influenceAny other transactionLease Rental paid4800000Approved2400000-1096000-50000Gufic Biosciences Limited******Gufic Chem Private Limited******Enterprise over which Key Managerial Personnel are able to exercise significant influenceAny other transactionInterest Free Security Deposit given against Lease-036000003600000Gufic Biosciences Limited******Tricon Enterprises Private Limited******Enterprise over which Key Managerial Personnel are able to exercise significant influenceSale of goods or services20000000Approved2450004850000Gufic Biosciences Limited******Gufic UK Limited******Wholly Owned Subsidiary of the CompanyInvestment-054120005412000Gufic Biosciences Limited******Gufic Prime Private Limited******Subsidiary of the CompanyInvestment-0600000600000Gufic Biosciences Limited******Veira Life FZE******Wholly Owned Subsidiary of the CompanyPurchase of goods or services800000000Approved41480000-325000Gufic Biosciences Limited******Veira Life FZE******Wholly Owned Subsidiary of the CompanyInvestment-047520004752000Gufic Biosciences Limited******Veira Life FZE******Wholly Owned Subsidiary of the CompanySale of goods or services800000000Approved0579000000Gufic Biosciences Limited******Veira Life FZE******Wholly Owned Subsidiary of the CompanyAny other transactionReimbursement of expenses paid1000000Approved7800000-780000Gufic Biosciences Limited******Gufic Ireland Limited******Wholly Owned Subsidiary of the CompanyInvestment-0102000102000Gufic Biosciences Limited******Mr. Jayesh P. Choksi******Promoter, Chairman & Managing DirectorRemunerationNot Applicable585600000Gufic Biosciences Limited******Mr. Jayesh P. Choksi******Promoter, Chairman & Managing DirectorAny other transactionPerquisitesNot Applicable10000000Gufic Biosciences Limited******Mr. Pranav J Choksi******Promoter, Chief Executive Officer & Whole Time DirectorRemunerationNot Applicable439200000Gufic Biosciences Limited******Mr. Pranav J Choksi******Promoter, Chief Executive Officer & Whole Time DirectorAny other transactionPerquisitesNot Applicable10000000Gufic Biosciences Limited******Mrs. Pooja P. Choksi******Immediate Relative of Key Managerial PersonnelAny other transactionReceiving of Services1900000Approved950000-71000-143000Gufic Biosciences Limited******Mr. Pankaj J. Gandhi******Whole Time DirectorRemunerationNot Applicable117800000Gufic Biosciences Limited******Mr. Pankaj J. Gandhi******Whole Time DirectorAny other transactionReimbursement of expenses paidNot Applicable162000-216000-10000Gufic Biosciences Limited******Dr. Anu Aurora******Independent DirectorAny other transactionSitting feesNot Applicable100000-680000Gufic Biosciences Limited******Mr. Kamal Kishore Seth******Independent DirectorAny other transactionSitting feesNot Applicable175000-680000Gufic Biosciences Limited******Mr. Akshya Kumar Mahapatra******Independent DirectorAny other transactionSitting feesNot Applicable175000-680000Gufic Biosciences Limited******Veira Life FZE******Wholly Owned Subsidiary of the CompanyAny other transactionReimbursement of expenses received2500000Approved022590000Gufic Biosciences Limited******Veira Life FZE******Wholly Owned Subsidiary of the CompanyAny other transactionAdvance against Import800000000Approved038230000The approved limit of Rs. 8,000 lakhs pertain to Purchase of Pharmaceutical Products and includes advances against importsGufic Biosciences Limited******Gufic Ireland Limited******Wholly Owned Subsidiary of the CompanyAny other transactionReimbursement of expenses received2500000Approved0278000043581000AuditedtrueM/s. Mittal Agarwal & Companytrue2028-04-30